Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
Spanish HIV HGM BioBank, Madrid, Spain.
Sci Rep. 2021 Dec 6;11(1):23477. doi: 10.1038/s41598-021-03020-5.
miRNAs have been extensively studied in pathological conditions, including viral infections, such as those provoked by HIV-1. Several cellular and circulating miRNAs are altered during HIV-1 infection, with either beneficial effects on host defenses or enhanced virus infectivity. Blood samples were collected in sterile EDTA tubes and plasma was separated and stored, as were PBMCs. RNA was isolated and reverse-transcribed. Finally, the miRNA gene expression profile was assessed using TaqMan Array Human microRNA Card A v2.0. A comprehensive statistical analysis was performed on the results obtained. This is the first study on miRNAs in HIV-1 paediatric patients, and a miRNA profile differentiating patients starting combination antiretroviral therapy (cART) at different times after HIV-1 diagnosis was established. Thirty-four miRNAs were observed to have different expression levels between the control group and the cART group. The data indicates the need to start cART as soon as possible after the establishment of HIV-1 infection to assure the best outcome possible. Finally, the selected 34 miRNAs may be used as biomarkers for prognosis and assessing therapy effectiveness. However, more research must be conducted to establish adequate quantitative correlations.
miRNAs 在病理条件下，包括病毒感染，如 HIV-1 感染，已经得到了广泛的研究。在 HIV-1 感染过程中，有几种细胞和循环 miRNA 发生改变，既有对宿主防御的有益影响，也有增强病毒感染力的作用。在无菌 EDTA 管中采集血液样本，并分离和储存血浆和 PBMCs。提取 RNA 并进行逆转录。最后，使用 TaqMan Array Human microRNA 卡 A v2.0 评估 miRNA 基因表达谱。对获得的结果进行了全面的统计分析。这是第一项关于 HIV-1 儿科患者 miRNA 的研究，建立了一种区分在 HIV-1 诊断后不同时间开始联合抗逆转录病毒治疗 (cART) 的患者的 miRNA 谱。观察到 34 种 miRNA 在对照组和 cART 组之间的表达水平不同。数据表明，需要在 HIV-1 感染确立后尽快开始 cART，以确保最佳结果。最后，选定的 34 种 miRNA 可作为预后和评估治疗效果的生物标志物。然而，需要进行更多的研究来建立适当的定量相关性。
